Real-world data of China: Analysis of HPV vaccine coverage and post-vaccination adverse reaction monitoring in Western Chinese provinces from 2018 to 2021

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–9. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Wanqing C, Rongshou Z, BP D, Siwei Z, Hongmei Z, Freddie B, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016:115–32. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Appendix 9: Cervical cancer diagnosis and treatment guidelines (2022 Edition). In: Notice on the issuance of guidelines for the diagnosis and treatment of cancer and hematologic diseases. By The General Office Of The National Health Commission; 2022. p. 1.
   Google Scholar
• W M-L. Study on the parental cognitive level and decision intention of HPV vaccination for junior middle school girls based on PMT. China: Bengbu Medical College; 2020.
   Google Scholar
• Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7. doi:10.1002/cncr.32003.
   PubMed Web of Science ®Google Scholar
• L P. Big data evaluation of the clinical epidemiology of cervical cancer in China’s mainland. Chinese Journal of Practical Gynecology and Obstetrics. 2018;34:41–5.
   Google Scholar
• L-H XQ-Y M, Li K, Xu W-L. The burden of disease of Chinese females cervical cancer from 1990 to 2019. Chinese Journal of Evidence-Based Medicine. 2021;21:648–53.
   Google Scholar
• L-P WH-Z Y, Ding G-H, Liu Y-Q. Epidemiological characteristics and trends of cervical cancer in cancer registries in Gansu province, 2009—2015. Practical Oncology Journal. 2021;35:224–30.
   Google Scholar
• WT C. Natural history of HPV infections. J Fam Pract. 2009;58(9).
   Google Scholar
• Wang, H., Zhao, F. and Zhao, Y, Sun X-D, Xu D-S. Expert consensus on immunoprophylaxis of human papillomavirus-related diseases(abridged). Chin J Vaccines Immun. 2019;25:718–35.
   Google Scholar
• Q Y-L. [Epidemiology of HPV infection and cervical cancer and perspective of HPV vaccination in Chinese women]. Chin J Epidemiol. 2007;28:937–40.
   Google Scholar
• Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations. Vaccine. 2017;35(43):5753–5755. doi:10.1016/j.vaccine.2017.05.069.
   PubMed Web of Science ®Google Scholar
• Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M. et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399. doi:10.1016/j.ypmed.2020.106399.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–63. doi:10.1016/S2214-109X(16)30099-7.
   PubMed Web of Science ®Google Scholar
• X-J HH-L F, Yu Q, Wang J-S. Market analysis and countermeasures of cervical cancer vaccine in China. China Biotechnology. 2020;40:96–101.
   Google Scholar
• S X-J. Analysis of HPV vaccination status and cognition of vaccinators in a province. China: Jilin University; 2022.
   Google Scholar
• National Health Commission of the People’s Republic of China document. Plan on adverse events following immunization surveillance in China. Chin J Vaccines Immun. 2011;17:72–81.
   Google Scholar
• NMPA. Notice on issuing the ‘national program for monitoring suspected adverse reactions to vaccination’. National Medical Products Administration; 2010. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/qita/20100603120001618.html
   Google Scholar
• Why, despite the obvious growth in batch issuance, Is the Nine-Valent HPV vaccine still in short supply? Tencent; 2021. https://new.qq.com/rain/a/20211231A03RZZ00.
   Google Scholar
• China National Institutes for Durg Control 2018-2022. Summary of public disclosure of products issued by the China Institute for Food and Drug Control - biological products batches. https://bio.nifdc.org.cn/pqf/search.do?formAction=pqfGgtz.
   Google Scholar
• Gilkey MB, Magnus BE, Reiter PL, McRee AL, Dempsey AF, Brewer NT. The vaccination confidence scale: a brief measure of parents’ vaccination beliefs. Vaccine. 2014;32(47):6259–65. doi:10.1016/j.vaccine.2014.09.007.
   PubMed Web of Science ®Google Scholar
• C-L LX-J Y, Zhu J, Yang J-P, Zhao S-X, Zhu Q, Chen, Y., Zhang, M. and He, F. Willingness to recommend non-expanded program on immunization vaccines and factors influencing willingness among healthcare workers in vaccination clinics in Baoshan district of Shanghai. Chin J Vaccines Immun. 2020;26:314–8.
   Google Scholar
• Kim HH, Washburn T, Marceau K, Raymond P. Human papillomavirus (HPV) vaccination coverage among Rhode Island adolescents, 2008-2014. R I Med J. (2013) 2016;99:34–7.
   Google Scholar
• Dorell C, Yankey D, Jeyarajah J, Stokley S, Fisher A, Markowitz L, Smith PJ. Delay and Refusal of Human Papillomavirus Vaccine for Girls, National Immunization Survey–Teen, 2010. Clin Pediatr (Phila). 2014;53(3):261–9. doi:10.1177/0009922813520070.
   PubMed Web of Science ®Google Scholar
• HY F, ZY N, and L YF. Analysis of mothers’ acceptance of HPV vaccination of adolescent girls in Xiamen. Zhonghua Yu Fang Yi Xue Za Zhi. 2018;52(1):38–42.
   PubMedGoogle Scholar
• LC-R PC, Zhang X, Li J. Knowledge and attitudes toward HPY and its vaccines among parents of middleschool students in Chengdu. Mod Prev Med. 2018;45:299–302+47.
   Google Scholar
• Brotherton JM, Murray SL, Hall MA, Andrewartha LK, Banks CA, Meijer D, Pitcher HC, Scully MM, Molchanoff L. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust. 2013;199(9):614–7. doi:10.5694/mja13.10272.
   PubMed Web of Science ®Google Scholar
• S-Q WK Z, Zhang Y-L. Application status of HPV vaccine in China. Chinese Journal Of Practical Gynecology And Obstetrics. 2019;35:1090–5.
   Google Scholar
• Van Damme P, Meijer C, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–12. doi:10.1016/j.vaccine.2016.06.056.
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RHM, Quek SC, da Silva DP. et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213–27. doi:10.1016/S0140-6736(14)60920-X.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Huang LM, Medina DM, Valencia A, Lin TY, Behre U, Catteau G, Thomas F, Descamps D. Four-year Follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years. J Adolesc Health. 2012;50(2):187–94. doi:10.1016/j.jadohealth.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ. et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine. 2012;30(28):4284–91. doi:10.1016/j.vaccine.2012.02.079.
   PubMed Web of Science ®Google Scholar
• Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006–2014--United States. MMWR Morb Mortal Wkly Rep. 2014;63:620–4.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J. Bocchini, J.A. Jr and Unger, E.R. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(5):1–30.
   PubMedGoogle Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta, H.S., Ball, R., Miller, N., Braun, M.M. and Markowitz, L.E. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–7. doi:10.1001/jama.2009.1201.
   PubMed Web of Science ®Google Scholar
• Šubelj M, Učakar V, Kraigher A, Klavs I. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013. Euro Surveill. 2016;21(14). doi:10.2807/1560-7917.ES.2016.21.14.30187.
   PubMedGoogle Scholar
• J-C WL-L L, Bai Q-R, Ren J, Shao H-Y, Huang Z-Y. Surveillance for coverage of human papillomavirus(HPV) vaccine and adverse events following immunization with HPV vaccine in Shanghai, 2017-2019. Chin J Vaccines Immun. 2020;26:322–5+48.
   Google Scholar
• R-D ZD-J H, Xiao J-X. Surveillance on adverse events following immunization with human papillomavirus vaccine in Fujian,2020. Strait J Preventive Med. 2021;27:10–12.
   Google Scholar
• Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019;11. 2019.10.1002/14651858.CD013479.
   Web of Science ®Google Scholar